Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study |
| |
| Authors: | J. B. Auliac C. Fournier C. Audigier Valette M. Perol A. Bizieux F. Vinas C. Decroisette Phan van Ho S. Bota Ouchlif R. Corre G. Le Garff P. Fournel N. Baize R. Lamy A. Vergnenegre D. Arpin B. Marin C. Chouaid R. Gervais |
| |
| Affiliation: | 1.Service de Pneumologie et oncologie thoracique,H?pital F Quesnay,Mantes la Jolie,France;2.Marseille,France;3.Toulon,France;4.Lyon,France;5.La Roche Sur Yon,France;6.Creteil,France;7.Prigny,France;8.Rouen,France;9.Rennes,France;10.Saint Brieux,France;11.Saint-Priest En Jarez,France;12.Angers,France;13.Lorient,France;14.Limoges Cedex,France;15.Macon,France;16.Limoges,France;17.Caen,France |
| |
| Abstract: | Retrospective studies suggested a benefit of first-line tyrosine kinase inhibitor (TKI) treatment continuation after response evaluation in solid tumors (RECIST) progression in epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients. The aim of this multicenter observational retrospective study was to assess the frequency of this practice and its impact on overall survival (OS). The analysis included advanced EGFR-mutated NSCLC patients treated with first-line TKI who experienced RECIST progression between June 2010 and July 2012. Among the 123 patients included (67?±?12.7 years, women: 69 %, non smokers: 68 %, PS 0–1: 87 %), 40.6 % continued TKI therapy after RECIST progression. There was no difference between the patients who did and did not continue TKI therapy with respect to progression-free survival (PFS1: 10.5 versus 9.5 months, p?=?0.054). Progressions were significantly less symptomatic in the TKI continuation group than in the discontinuation group (18 % vs. 37 %, p?=?0.001), >1 one metastatic site (HR 1.96, 95 %CI: 1.06-3.61, p?=?0.02) at diagnosis, and a trend towards a higher risk of death in cases of TKI discontinuation after progression (HR 1.62, 95 %CI: 0.98-2.67, p?=?0.00001) and >1 metastatic site (HR 2.54, 95 %CI: 1.24-5.21, | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
